Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Guanylate Cyclase Activators" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A guanylate cyclase activator (or "GUCA") is one of group of proteins which upregulates guanylate cyclase. It is also known as guanylate cyclase-activating protein, with the abbreviation "GCAP". Mutations can be associated with vision defects.
Soluble guanylate cyclase activators
A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME CORP
Soluble guanylate cyclase activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble Guanylate Cyclase Activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
Owner:MERCK SHARP & DOHME LLC
Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
A compound of Formula Ior a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
Owner:MERCK SHARP & DOHME LLC
Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
The present invention relates generally to a method for the treatment of renal failure or renal hypertension and, more particularly, for improving the recovery from acute renal failure or renal hypertension by treatment with activators of soluble guanylate cyclase or stimulators of guanylate cyclase.
Owner:BAYER SCHERING PHARMA AG
Soluble guanylate cyclase activators
This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
Owner:BOEHRINGER INGELHEIM INT GMBH
Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
InactiveUS20050181066A1Improvement in gas exchange functionSuitable for treatmentBiocideAntipyreticGuanylate Cyclase ActivatorsIntensive care medicine
The invention relates to the novel use of guanylate cyclase activators for the treatment of partial and global respiratory failure.
Owner:ALTANA PHARMA
Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
A compound of Formula Ior a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
Owner:MERCK SHARP & DOHME LLC
Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
Owner:MERCK SHARP & DOHME LLC
Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
Owner:BOEHRINGER INGELHEIM INT GMBH
Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
ActiveUS20170197940A1Reduced bioavailabilityOrganic active ingredientsSenses disorderMedicineActive agent
Owner:NOVARTIS AG
Soluble guanylate cyclase activators
Owner:BOEHRINGER INGELHEIM INT GMBH
Alkoxy pyrazoles as soluble guanylate cyclase activators
Owner:BOEHRINGER INGELHEIM INT GMBH
Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
Owner:NOVARTIS AG
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
ActiveUS20180193343A1Organic active ingredientsOrganic chemistryMedicineGuanylate Cyclase Activators
A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators and their use
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
Owner:MERCK SHARP & DOHME LLC
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
ActiveUS20180147208A1Organic active ingredientsOrganic chemistryMedicineGuanylate Cyclase Activators
A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or pharmaceutically acceptable salt thereofs, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or pharmaceutically acceptable salts thereof.
Owner:MERCK SHARP & DOHME LLC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com